Savara (SVRA) announced the European Patent Office notified the company of its intention to grant a patent application covering the liquid formulation of Molbreevi, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
- Savara rumor highlighted in Betaville blog
- Savara issues patent for Molbreevi from European Patent Office
- Savara’s MOLBREEVI: Promising Potential in APAP Market with Strategic Expert Engagement
- Savara Inc. Reports Q3 2025 Financial Results